Search bioRxiv⌕ Search

Biology subjects

Gamboa, A.

Publications and source records attributed to Gamboa, A..

4 recordsLinked to original sources

Glial cell and perineuronal net interactions in the dorsal striatum of aged mice

CommentaryElucidating how normal aging increases vulnerability to neurodegeneration remains a major gap in our understanding of disease risk and progression. The dorsal striatum serves as the primary input nucleus of the basal ganglia and is a key region implicated in multiple neurodegenerative diseases (NDDs) (1). In Colon et al. 2025 (2), we examined the impact of normal aging on neuroinflammatory signaling and perineuronal net (PNN) homeostasis within the dorsal striatum. We observed age-associated shifts in the inflammatory landscape and evidence of increased microglial activation, yet PNN homeostasis was largely preserved (2). PNNs are highly organized extracellular matrix (ECM) specializations that preferentially enwrap the soma and proximal dendrites of fast-spiking GABAergic parvalbumin (PV) interneurons, where they contribute to the regulation of synaptic plasticity and provide protection against oxidative stress (3,4). Building on these findings, we developed a working hypothesis to explain the apparent preservation of PNN homeostasis despite an aging-associated pro-inflammatory environment. The shift toward a pro-inflammatory milieu, together with increased gliosis and phagocytic activity, would be expected to impact the maintenance and integrity of perineuronal nets. The observed increase in phagocytosis-related markers may reflect microglia-directed activity as well as contributions from additional central nervous system (CNS) cell populations. Microglia are specialized embryonic-derived myeloid cells that serve as the resident immune cells of the brain and contribute to PNN homeostasis under physiological conditions (5). In Colon et al. 2025, we observed evidence of microgliosis (e.g., morphological changes, Iba1, Trem2) along with elevated expression of markers associated with phagocytosis (e.g., Cd68) and extracellular matrix-modifying proteases (e.g., Mmp9, Adam17) capable of cleaving key PNN components (2). Importantly, Cd68 expression is not exclusive to microglia and has been detected in brain infiltrating macrophages, reactive astrocytes, and neutrophils during inflammation (6-8). Thus, increased Cd68 levels may not solely reflect microglial phagocytic activation but may also reflect astrocyte reactivity and phagocytic phenotypes. Furthermore, astrocytes are the most abundant glial cell in the brain, and they play a major role in maintaining CNS homeostasis by regulating extracellular neurotransmitter concentrations, providing metabolic support, contributing to the synthesis and remodeling of PNN components, and modulating neuronal communication through their involvement in the tetrapartite synapse (9-12). Astrocytes can also phagocytosis microglial debris, myelin, and synapses (7). To better define the cellular source of phagocytic activity and its relationship to PNN remodeling in aging, we performed immunostaining for microglia (Iba1+), astrocytes (GFAP+), phagolysosomal activity (CD68+), and PNNs using Wisteria floribunda agglutinin (WFA+), enabling us to assess the spatial relationship between phagocytosis and PNN components.

neuroscience↗

Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma

Mantle cell lymphoma (MCL) is a genetically and clinically heterogeneous B-cell malignancy. We studied two MCL cohorts with differing treatment patterns: one enriched for immunochemotherapy, the other for chemotherapy alone. TP53 alterations were consistently associated with poor prognosis, whereas ATM mutations correlated with improved outcomes following rituximab-based chemotherapy. Based on recurrent genetic events, six clusters were identified and refined into three prognostic groups: high-risk (TP53 mutations and deletions at 17p13.3, 13q14.2, and 19p13.3), intermediate-risk (ATM and epigenetic regulator mutations, or gains at 8q/17q/15q), and low-risk (lacking TP53 alterations, rare ATM mutations without 11q deletions, gains at 3q, deletions at 6q). Transcriptomic analysis revealed enrichment of proliferation, metabolism-promoting gene signatures in high-risk; angiogenesis and NOTCH signaling in intermediate-risk; and proinflammatory-related (i.e., IFN, TNF) in low-risk MCLs. Multi-proteomic spatial profiling using imaging mass cytometry (IMC) demonstrated enrichment of CD8 T cells with high expression of exhaustion markers and dominant population of myeloid cells skewed toward an M2-like phenotype. Compared to ATM-perturbed tumors, TP53-perturbed tumors exhibited enriched SOX11 tumor cells and enhanced tumor-immune cell interactions. Functional analysis revealed that p53 represses BCR signaling through PTPN6 activation. Collectively, these findings highlight distinct molecular and immune landscapes and reveal therapeutic vulnerabilities in high-risk TP53-altered MCL.

cancer biology↗

Imaging Mass Cytometry-Driven Spatial Analysis and Biomarker Discovery in Hodgkin Lymphoma

The biology of tumors is suffused with spatial interactions, such as tumor-immune signaling through localized cytokine/ligand secretion, cell-cell contacts, and checkpoint ligand/receptor signaling. Hodgkin Lymphoma (HL) can serve as a study paradigm for tumor microenvironment (TME) architecture as the defining pathological feature is the scarcity of the malignant Hodgkin and Reed Sternberg (HRS) cells, leaving a diverse and predominantly immune cell rich tumor microenvironment (TME) with complex tumor-immune interactions. Previous studies have identified TME features that are prognostic and predictive, however these studies did not consider the entirety of TME cellular ecosystems, including precisely defined immune cell subsets with opposing inflammatory and immune-suppressive effects, as a determinant for differential clinical course of HL patients. Here we use Imaging Mass Cytometry (IMC) with 42 antibody markers to profile tumors from 93 patients with HL. Our cohort consists of relapsed/refractory HL with matched diagnostic and relapsed biopsies, and we present a bioinformatic pipeline to profile 10 major cell lineages and their subtypes including spatial interaction mapping. Our pipeline identifies putative biomarker candidates with a focus on "rosettes" - local aggregates of immune cells around single tumor cells. In addition to validating existing biomarkers centered on CD68+ macrophages, GranzymeB+CD8+ T cells, and others in HL, we propose new biomarkers based on localized interactions between HRS cells and aggregating CD4+ and CD8+ T cells and macrophages involving the immune checkpoints PD1/PDL1, LAG3, and Galectin9. This study serves as a broad tissue imaging resource for multi-timepoint biopsies in HL, and a computational resource and pipeline for users of IMC and other multiplexed imaging studies to perform tissue analysis and biomarker candidate testing with any tissue type.

cancer biology↗

The spatially resolved tumor microenvironment predicts treatment outcome in relapsed/refractory Hodgkin lymphoma

PURPOSEAbout a third of relapsed or refractory classic Hodgkin lymphoma (r/r CHL) patients succumb to their disease after high-dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT). Here, we aimed to describe spatially resolved tumor microenvironment (TME) ecosystems to establish novel biomarkers associated with treatment failure in r/r CHL. METHODSWe performed imaging mass cytometry (IMC) on 169 paired primary diagnostic and relapse biopsies using a marker panel specific for CHL biology. For each cell type in the TME, we calculated a spatial score measuring the distance of nearest neighbor cells to the malignant Hodgkin Reed Sternberg cells within close interaction range. Spatial scores were used as features in prognostic model development for post-ASCT outcomes. RESULTSHighly multiplexed IMC data revealed shared TME patterns in paired diagnostic and early relapse/refractory CHL samples, whereas TME patterns were more divergent in pairs of diagnostic and late relapse samples. Integrated analysis of IMC and single cell RNA sequencing data identified unique architecture defined by CXCR5+ HRS cells and their strong spatial relationship with CXCL13+ macrophages in the TME. We developed a prognostic assay ( RHL4S) using four spatially resolved parameters, CXCR5+ HRS cells, PD1+CD4+ T cells, tumor-associated macrophages, and CXCR5+ B cells, which effectively separated patients into high-risk vs low-risk groups with significantly different post-ASCT outcomes. The RHL4S assay was validated in an independent r/r CHL cohort using a multicolor immunofluorescence assay. CONCLUSIONSWe identified the interaction of CXCR5+ HRS cells with ligand-expressing CXCL13+ macrophages as a prominent crosstalk axis in relapsed CHL. Harnessing this TME biology, we developed a novel prognostic model applicable to r/r CHL biopsies, RHL4S, opening new avenues for spatial biomarker development.

cancer biology↗